Cancer Diagnostics Market by Test Type (Genetic Tests, Imaging, Laboratory Tests, Endoscopy, Biopsy, and others), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, and Others), End User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, and Others) - Global Analysis & Forecast 2020-2030

Report ID : 281  |  Published Date : Jun 2020  |  Pages : 160  |  Region : Global  |  Report Code : MD-77





Cancer Diagnostics MarketOverview and Introduction                                                           

Cancer diagnostics comprise of many tests such as genetic tests, imaging, laboratory tests, endoscopy, biopsy etc. Cancer diagnosticsensures early detection of various cancers and helps to build a course of treatment. Various diagnostic tests helpdoctors to plan treatment and also allow for a greater degree of personalized medicine.

The global cancer diagnostics market is majorly driven byincreasing incidence of variouscancers coupled with an urge of their early diagnosis. FDA assistance for development of biomarkers,initiatives undertaken by various governments and health organizations globally to spread awareness about cancer, launch of novel flow cytometry reagents for drug discovery and diagnostics are other prominent factors that are likely to provide impetus to the market.

Favorable investment climate, rising research collaborations, growing prominence of personalized medicine and companion diagnostics, development of mass cytometry and the combination of cell-and bead-based flow cytometry technologies are some of the key factors that are likely to open growth avenues for the market.

The globalcancer diagnostics marketis segmented by test type, cancer type, end user, and region.

Cancer Diagnostics Market, By Test Type

Based on test type, thecancer diagnostics marketcan besegmentedinto genetic tests, imaging, laboratory tests, endoscopy, biopsy, and others. The imaging test segment holds the largest share of the market predominantly dueto its agility. Imaging tests also facilitates non-invasive and pain-free diagnostic solutions. Precision of the imaging tests and technological advancements are other key factors that are expected to spur its demand in the coming years.

Cancer Diagnostics Market, By Cancer Type

Based on cancer type, the market can be bifurcated into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, and others. The breast cancersegment is anticipated to witness highest CAGR during forecast period, owing to increasing number of breast cancer cases. According to World Cancer Research Fund International, more than 2 million new cases were diagnosed in 2018.

Cancer Diagnostics Market, By End User

Based on the end users, the market can besegmented intohospitals, diagnostic laboratories, diagnostic imaging centers, and others. The hospitals segment is estimated to account for the largest market share globally. The large share of this segment can be attributed to accessibility of latest technologies in hospitals and the fact that maximum number of diagnostic tests are carried out in hospitals.

Cancer Diagnostics Market, By Region

The globalcancer diagnostics marketcan be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the cancer diagnostics market followed by Europe and Asia Pacific. North America is expected to continue its dominance inthe cancer diagnostics marketduring the forecast period owing to factors such as growing geriatric populations, increasing incidence of cancers, and due to presence of prominent regional players, among others. 

Cancer Diagnostics Market: Prominent Players

Some of the prominent players operating in the global cancer diagnostics market are GE Healthcare, Abbott Laboratories, Siemens Healthineers AG, F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Illumina, Inc., Hologic, Inc., Koninklijke Philips N.V.,Agilent Technologies, Inc., QIAGEN,among others.